Imagine your skin as a high-tech security gate that can be tricked into training your immune system more effectively. This project uses that trick to create a vaccine that clears out the toxic protein clumps causing Parkinson's. It also includes a simple blood-like test to catch the disease before the brain is permanently damaged.
Parkinson's Disease lacks curative therapies and early diagnosis tools, leaving 8.5 million people with treatments that only manage symptoms without stopping disease progression.
A proprietary WISIT vaccine platform for aSyn targeting and an EV-based biomarker assay for early liquid biopsy diagnosis.
If you are a biotech vaccine developer dealing with low immune responses in traditional vaccines — this project developed the WISIT platform that uses skin dendritic cells to create stronger, more specific responses with fewer adjuvants.
If you are a diagnostic provider dealing with the lack of early Parkinson's detection — this project developed an extracellular vesicle (EV)-based biomarker assay that enables early diagnosis via liquid biopsies.
If you are a clinic network dealing with the high financial burdens of 8.5 million PD patients — this project developed a disease-modifying treatment and diagnostic tool to intervene before irreversible brain damage occurs.
Based on available project data, the objective is to achieve a 'cheap and effective' disease-modifying treatment, though specific price points are not listed.
The project includes the manufacture of GMP-grade constructs, which is a requirement for industrial-scale pharmaceutical production.
The project utilizes the proprietary WISIT platform owned by the coordinator; however, specific licensing terms for the 12 partners are not provided in the dataset.
The project runs from 2023-04-01 to 2027-03-31, aiming to translate results into first-in-human Phase I/Ib clinical trials.
The EV-based biomarker assay is designed for liquid biopsies and is specifically intended to be suitable for point-of-care use.
The consortium is heavily industry-weighted with 8 industrial partners (67% ratio), 7 of which are SMEs. This strong commercial presence, spanning 6 countries (AT, DE, FR, HU, NL, UK), suggests a high focus on commercial translation and GMP manufacturing rather than purely academic research.
Contact TRIDEM BIOSCIENCE GMBH & CO KG in Austria
Contact us to explore licensing opportunities for the WISIT platform.
